Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Pseudomyxoma Peritonei × 90 days × Clear all

Phase

Phase 2 3 Phase NA 2 Phase 3 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 21 Glioma 14 Glioblastoma 14 Multiple Myeloma 12 Prostatic Neoplasms 11 Pancreatic Neoplasms 11 Neoplasms 11 Lung Neoplasms 7 Hematologic Neoplasms 7 Colorectal Neoplasms 7 Brain Neoplasms 7 Recurrence 6 Ovarian Neoplasms 6 Melanoma 6 Triple Negative Breast Neoplasms 5 Sarcoma 5 Lymphoma 5 Leukemia, Myeloid, Acute 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Colonic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Skin Neoplasms 4 Fallopian Tube Neoplasms 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Lymphoma, B-Cell 3 Leukemia 3 Burkitt Lymphoma 3

Interventions

tislelizumab 1 molgramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡